Journal of Radiation Research最新文献

Prospective study of a rotating gantry with scanning beams of carbon-ion radiotherapy for choroidal malignant melanoma. 旋转龙门碳离子放射治疗脉络膜恶性黑色素瘤的前瞻性研究。

IF 1.9 4区医学

Journal of Radiation Research Pub Date : 2025-06-10 DOI: 10.1093/jrr/rraf030

Masaru Wakatsuki, Hirokazu Makishima, Shuri Aoki, Nao Kobayashi, Hiroshi Tsuji, Hitoshi Ishikawa, Shigeru Yamada, Atsushi Mizota

{"title":"Prospective study of a rotating gantry with scanning beams of carbon-ion radiotherapy for choroidal malignant melanoma.","authors":"Masaru Wakatsuki, Hirokazu Makishima, Shuri Aoki, Nao Kobayashi, Hiroshi Tsuji, Hitoshi Ishikawa, Shigeru Yamada, Atsushi Mizota","doi":"10.1093/jrr/rraf030","DOIUrl":"https://doi.org/10.1093/jrr/rraf030","url":null,"abstract":"To evaluate the safety of a rotating gantry with scanning beams of carbon-ion radiotherapy (C-ion RT) for choroidal malignant melanoma. A prospective study of C-ion RT using a rotating gantry with scanning beams for choroidal malignant melanoma was initiated at the National Institute for Quantum Science and Technology, QST Hospital in March 2018. The inclusion criteria were as follows: (i) clinically diagnosed ocular/choroidal malignant melanoma; (ii) tumor measurable by imaging tests; (iii) score of 0-2 on the Eastern Cooperative Oncology Group Performance Status scale and (iv) ability to provide consent for treatment. All patients received 68 Gy in four fractions of C-ion RT by a rotating gantry with scanning beams. Between April 2018 and July 2019, 21 patients were enrolled and underwent C-ion RT as planned. All 21 patients completed the treatment schedule and the 3-year follow-up period. The median duration of follow-up was 43 months (range, 35.2-54.6 months). Regarding late normal tissue responses, three of the 21 patients developed grade 2 neovascular glaucoma; however, no other late grade ≥2 acute toxicities were observed. During the 3-year study period, all 21 patients survived with no local recurrence; none of the patients underwent enucleation. Three cases showed liver metastasis. The 3-year local control, overall survival and eye-retention rates were all 100%. The results of this prospective study confirmed that the effectiveness and safety of this method are equivalent to those of conventional passive irradiation methods, although the number of cases was small. The results of this prospective study confirmed that the effectiveness and safety of this method are equivalent to those of conventional passive irradiation methods, although the number of cases was small.","PeriodicalId":16922,"journal":{"name":"Journal of Radiation Research","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144266471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Relative risk of cardiac mortality and dosimetric comparison among three-dimensional radiotherapy, volume-modulated arc therapy and proton beam in vertebral-body reduced-dose craniospinal irradiation. 三维放疗、体积调节电弧治疗和质子束椎体-颅脊柱低剂量照射中心脏死亡率的相对风险和剂量学比较。

IF 1.9 4区医学

Journal of Radiation Research Pub Date : 2025-06-10 DOI: 10.1093/jrr/rraf032

Chonnipa Nantavithya, Anussara Prayongrat, Sornjarod Oonsiri, Kanjana Shotelersuk

{"title":"Relative risk of cardiac mortality and dosimetric comparison among three-dimensional radiotherapy, volume-modulated arc therapy and proton beam in vertebral-body reduced-dose craniospinal irradiation.","authors":"Chonnipa Nantavithya, Anussara Prayongrat, Sornjarod Oonsiri, Kanjana Shotelersuk","doi":"10.1093/jrr/rraf032","DOIUrl":"https://doi.org/10.1093/jrr/rraf032","url":null,"abstract":"We aimed to compare dose to organs at risk (OARs) and the excess relative risk (ERR) of cardiac mortality among three-dimensional conformal radiotherapy (3D-CRT), volume modulated arc therapy (VMAT) and proton beam therapy (PBT) in craniospinal irradiation (CSI). CSI plans of 3D-CRT, VMAT and PBT were generated. Vertebral body reduced dose (VBR)-CSI according to the International Society of Paediatric Oncology recommendation was used for VMAT and PBT. We delineated two sets of target volumes, i.e. target volume (TV) 1 for brain and thecal sac and TV2 for the vertebral body. Two sets of CSI dose, 23.4 and 36 Gy, were prescribed for TV1, and VBR doses, 18.4 and 20 Gy, were prescribed for TV2. For 3D-CRT, we prescribed a dose only to cover TV1. For VMAT and PBT, 23.4/18.4Gy and 36/20 Gy in 13 and 20 fractions were optimized. To evaluate the ERR of cardiac mortality compared with the normal population, we incorporate the mean heart dose with the linear model. In a total of eight patients, 48 treatment plans were generated (24 plans for each dose set). PBT showed the lowest mean dose to all OARs, i.e. heart, lung, liver, kidney, esophagus, oral cavity, thyroid and vertebral body. PBT showed significantly less ERR of cardiac mortality compared with 3D-CRT and VMAT for both 23.4 and 36 Gy prescriptions. With VBR-CSI, PBT reduced the mean dose to all OARs and significantly reduced the ERR of cardiac mortality compared with 3D-CRT and VMAT. The advantage of PBT was manifest, especially with high-dose CSI.","PeriodicalId":16922,"journal":{"name":"Journal of Radiation Research","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144266472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stereotactic body radiation therapy for renal cell carcinoma: a small number of initial clinical experiences. 立体定向放射治疗肾细胞癌：少量初步临床经验。

IF 1.9 4区医学

Journal of Radiation Research Pub Date : 2025-06-03 DOI: 10.1093/jrr/rraf028

Takahiro Aoyama, Yutaro Koide, Hidetoshi Shimizu, Tomoki Kitagawa, Tohru Iwata, Shingo Hashimoto, Hiroyuki Tachibana, Takeshi Kodaira

{"title":"Stereotactic body radiation therapy for renal cell carcinoma: a small number of initial clinical experiences.","authors":"Takahiro Aoyama, Yutaro Koide, Hidetoshi Shimizu, Tomoki Kitagawa, Tohru Iwata, Shingo Hashimoto, Hiroyuki Tachibana, Takeshi Kodaira","doi":"10.1093/jrr/rraf028","DOIUrl":"https://doi.org/10.1093/jrr/rraf028","url":null,"abstract":"Stereotactic body radiation therapy (SBRT) has emerged as a promising and minimally invasive treatment option for patients with renal cell carcinoma (RCC). This study presents our initial clinical experiences with treatments following our center's protocol, which was formulated based on both national and international evidence. Six patients who had undergone renal SBRT at our center from January 2021 to December 2023 were included. Treatment planning used computed tomography (CT) and magnetic resonance imaging, with respiratory management conducted through breath-hold or free-breathing techniques. The prescribed dose was primarily 48 Gy in three fractions, with increased fractionations when dose constraints were challenging to achieve. Dose constraints were met for all patients, and treatment planning adhered to protocol guidelines. After the confirmation of cone-beam CT (CBCT) images by physicians, radiation was delivered. Five out of six patients completed the planned treatment, whereas one discontinued the treatment midway (the causal relationship to radiation therapy was unclear). Dose-volume histogram analysis revealed that doses to organs at risk depended on the position and size of the planning target volume but remained within acceptable limits for all cases. The intrafractional patient motion was 2.7 mm, as calculated from the pre- and post-CBCT images, confirming the appropriateness of a 3-mm setup margin. Although this study provides initial insights, further clinical trials are warranted to establish standardized protocols and optimize treatment strategies for RCC. In the future, it is also necessary to generate evidence that is tailored to the current situation in Japan.","PeriodicalId":16922,"journal":{"name":"Journal of Radiation Research","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144216201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radiotherapy treatment planning for esophageal cancer: JASTRO guidelines 2024 for radiotherapy treatment planning. 食管癌放疗治疗计划：JASTRO指南2024放疗治疗计划。

IF 1.9 4区医学

Journal of Radiation Research Pub Date : 2025-06-03 DOI: 10.1093/jrr/rraf029

Keiichi Jingu, Keiji Nihei, Yoshinori Ito, Masahiko Okamoto, Hiroshi Doi, Hirofumi Ogawa, Masakatsu Onozawa, Terufumi Kawamoto, Norio Katoh, Atsuya Takeda, Hirokazu Makishima, Hiroshi Mayahara, Hideya Yamazaki, Keiko Nemoto Murofushi, Kayoko Tsujino, Hiroshi Igaki, Takashi Uno

{"title":"Radiotherapy treatment planning for esophageal cancer: JASTRO guidelines 2024 for radiotherapy treatment planning.","authors":"Keiichi Jingu, Keiji Nihei, Yoshinori Ito, Masahiko Okamoto, Hiroshi Doi, Hirofumi Ogawa, Masakatsu Onozawa, Terufumi Kawamoto, Norio Katoh, Atsuya Takeda, Hirokazu Makishima, Hiroshi Mayahara, Hideya Yamazaki, Keiko Nemoto Murofushi, Kayoko Tsujino, Hiroshi Igaki, Takashi Uno","doi":"10.1093/jrr/rraf029","DOIUrl":"https://doi.org/10.1093/jrr/rraf029","url":null,"abstract":"The Japanese Society for Radiation Oncology (JASTRO) Guidelines for Radiotherapy Treatment Planning have been revised every four years to incorporate the latest findings since the publication of the first edition in 2004. This is a review which presents the 2024 JASTRO Guidelines for radiotherapy treatment planning for esophageal cancer in English. Regarding the treatment of esophageal cancer, various new findings have emerged over the past 4 years, leading to significant updates in the 2020 edition, particularly in the following six areas: (i) additional details on indications for superficial cancer, (ii) inclusion of clinical trial results (JCOG1109) for neoadjuvant chemotherapy and chemoradiotherapy in locally advanced cases in Japan, (iii) updated references on prophylactic lymph node irradiation, (iv) updates on IMRT, (v) revisions in accordance with the 5th edition of the Esophageal Cancer Treatment Guidelines, and (vi) additions of FOLFOX to concurrent chemotherapy regimens.","PeriodicalId":16922,"journal":{"name":"Journal of Radiation Research","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144216200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The glymphatic system in oncology: from the perspective of a radiation oncologist. 肿瘤学中的淋巴系统：从放射肿瘤学家的角度。

IF 1.9 4区医学

Journal of Radiation Research Pub Date : 2025-06-03 DOI: 10.1093/jrr/rraf027

Kentaro Nishioka, Mariko Kawamura, Mami Iima, Daiju Ueda, Rintaro Ito, Tsukasa Saida, Ryo Kurokawa, Koji Takumi, Akihiko Sakata, Satoru Ide, Maya Honda, Masahiro Yanagawa, Shunsuke Sugawara, Seitaro Oda, Tadashi Watabe, Keitaro Sofue, Kenji Hirata, Shinji Naganawa

{"title":"The glymphatic system in oncology: from the perspective of a radiation oncologist.","authors":"Kentaro Nishioka, Mariko Kawamura, Mami Iima, Daiju Ueda, Rintaro Ito, Tsukasa Saida, Ryo Kurokawa, Koji Takumi, Akihiko Sakata, Satoru Ide, Maya Honda, Masahiro Yanagawa, Shunsuke Sugawara, Seitaro Oda, Tadashi Watabe, Keitaro Sofue, Kenji Hirata, Shinji Naganawa","doi":"10.1093/jrr/rraf027","DOIUrl":"https://doi.org/10.1093/jrr/rraf027","url":null,"abstract":"The brain and spinal cord, which constitute the central nervous system, were historically considered immune-privileged sites, as it was believed they lacked an equivalent to the systemic lymphatic system. However, in 2013, a pathway facilitating the clearance of waste products through the brain parenchyma via the perivascular space was proposed, garnering attention as the 'glymphatic system'. Similar to the systemic lymphatic system, the glymphatic system plays a critical role in immune responses and has been implicated not only in Alzheimer's disease and inflammatory brain disorders but also in conditions such as hydrocephalus and glaucoma, which are associated with cerebrospinal fluid circulation impairments. Recent studies have suggested that dysfunction of the glymphatic system may promote the progression of brain tumors and reduce the efficacy of immune responses and pharmacological therapies targeting tumors. Radiotherapy is a major treatment option for brain tumors; however, while it can enhance immune responses against tumors, it may also suppress these responses at the same time. Additionally, cranial irradiation has been suggested to impair the function of the glymphatic system. This review provides an overview of the structure and functional evaluation methods of the glymphatic system, summarizes the effects of its dysfunction on brain tumor treatment, and explores recent findings on the impact of radiation therapy on glymphatic system functioning. Lastly, it also explores the potential for radiation therapy strategies that account for their effects on the glymphatic system.","PeriodicalId":16922,"journal":{"name":"Journal of Radiation Research","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144216202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Occupational radiation exposure of therapists in clinical use of spot scanning proton-carbon ion synchrotron systems. 临床使用点扫描质子-碳离子同步加速器系统时治疗师的职业辐射暴露。

IF 1.9 4区医学

Journal of Radiation Research Pub Date : 2025-05-30 DOI: 10.1093/jrr/rraf023

Zhulei Liu, Dan You, Dan Zhou, Ruirui Bu, Yao Li, Xiaowa Wang

{"title":"Occupational radiation exposure of therapists in clinical use of spot scanning proton-carbon ion synchrotron systems.","authors":"Zhulei Liu, Dan You, Dan Zhou, Ruirui Bu, Yao Li, Xiaowa Wang","doi":"10.1093/jrr/rraf023","DOIUrl":"https://doi.org/10.1093/jrr/rraf023","url":null,"abstract":"This study addresses the escalating radiation safety concerns among medical professionals due to the rising application of proton and carbon ion radiotherapy. It evaluates the occupational radiation exposure faced by therapists when utilizing the Siemens IONTRIS Proton-Carbon Ion System. Through random sampling of 80 patients treated between January and June 2024, we recorded particle types and counts and measured dose rates using a photon/neutron radiation dose meter. Notably, 1 min post-treatment, the dose rate peaked at 16.00 μSv/h near the tumor's skin surface, showing a significant correlation with particle count. The therapist's standing position and the surfaces of the range shifter and ripple filter registered average dose rates of 1.25 μSv/h and 3.63 μSv/h, 0.33 μSv/h, respectively. Other points averaged 0.08 μSv/h, with no neutron detection. The study concludes that the annual average occupational exposure for therapists, at ~300 μSv, is significantly below the International Commission on Radiological Protection's recommended dose equivalent limit, confirming the safety of the Siemens IONTRIS device in clinical settings.","PeriodicalId":16922,"journal":{"name":"Journal of Radiation Research","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144187236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Retraction of: Fractionated irradiation-induced EMT-like phenotype conferred radioresistance in esophageal squamous cell carcinoma. 分次辐照诱导的emt样表型与食管鳞状细胞癌的放射耐药有关。

IF 1.9 4区医学

Journal of Radiation Research Pub Date : 2025-05-30 DOI: 10.1093/jrr/rraf033

引用次数: 0

Suppression of cancer stem-like cell radioresistance by inhibiting AMPK signaling. 通过抑制AMPK信号传导抑制癌症干细胞的辐射抗性。

IF 1.9 4区医学

Journal of Radiation Research Pub Date : 2025-05-23 DOI: 10.1093/jrr/rraf015

Tsutomu Shimura, Honoka Nara, Mayu Yamazaki, Megumi Sasatani, Akira Ushiyama

{"title":"Suppression of cancer stem-like cell radioresistance by inhibiting AMPK signaling.","authors":"Tsutomu Shimura, Honoka Nara, Mayu Yamazaki, Megumi Sasatani, Akira Ushiyama","doi":"10.1093/jrr/rraf015","DOIUrl":"10.1093/jrr/rraf015","url":null,"abstract":"Cancer stem cell (CSC) radioresistance is a major cause of radiotherapy (RT) failure and tumor recurrence. The molecular target for eradicating CSCs has not been identified despite research efforts to overcome tumor radioresistance. The adenosine monophosphate-activated protein kinase (AMPK) is responsible for transmitting nuclear DNA damage signals to the mitochondria, which in turn generate adenosine triphosphate to execute a DNA damage response. Disruption of this mitochondria-mediated genomic defense mechanism may be an effective strategy to enhance the cytotoxic efficacy of RT. Here, we investigated the potential efficacy of the pan-AMPK inhibitor dorsomorphin (Dor) in preventing CSC radioresistance. Radioresistant cancer stem-like cells were derived from the human liver cancer cell line HepG2 (HepG2 82FR-31NR). The radiosensitizing effect of Dor was then examined in HepG2 82FR-31NR cell cultures by clonogenic assays. Low-dose Dor markedly suppressed the recovery of HepG2 cancer stem-like cells after radiation but had little effect on normal fibroblast proliferation and survival, whether applied alone or in combination with radiation. In conclusion, this study strongly suggests that Dor treatment can radiosensitize cancer stem-like cells at doses that have no significant cytotoxic effects on normal human fibroblasts.","PeriodicalId":16922,"journal":{"name":"Journal of Radiation Research","volume":" ","pages":"227-233"},"PeriodicalIF":1.9,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12100479/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144026540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimizing dwell time weight for interstitial needles in intracavitary/interstitial hybrid brachytherapy: balancing tumor coverage with organ sparing using the inverse planning technique. 优化腔内/间质混合近距离放疗中间质针的停留时间权重：利用逆计划技术平衡肿瘤覆盖与器官保留。

IF 1.9 4区医学

Journal of Radiation Research Pub Date : 2025-05-23 DOI: 10.1093/jrr/rraf025

Jun Takatsu, Naoya Murakami, Noriyuki Okonogi, Tatsuya Inoue, Kotaro Iijima, Yoichi Muramoto, Yasuo Kosugi, Terufumi Kawamoto, Tatsuki Karino, Yasuhisa Terao, Naoto Shikama

{"title":"Optimizing dwell time weight for interstitial needles in intracavitary/interstitial hybrid brachytherapy: balancing tumor coverage with organ sparing using the inverse planning technique.","authors":"Jun Takatsu, Naoya Murakami, Noriyuki Okonogi, Tatsuya Inoue, Kotaro Iijima, Yoichi Muramoto, Yasuo Kosugi, Terufumi Kawamoto, Tatsuki Karino, Yasuhisa Terao, Naoto Shikama","doi":"10.1093/jrr/rraf025","DOIUrl":"10.1093/jrr/rraf025","url":null,"abstract":"The recommended dwell time weight of the needle in intracavitary/interstitial hybrid brachytherapy (HBT) has been 10-20%. This study aimed to investigate the correlation between the weight constraint of the needle and normal organ doses in uterine cervical cancer HBT. This study included 30 cervical cancer patients who received HBT with tandem/ovoid applicators. In our clinical practice, treatment plans were generated without the constraint of the dwell time weight of the needle. The cases where this weight exceeded 20% were replanned. An inverse planning technique with locking downscaled needle dwell time was used to reproduce isodose lines of clinical plans. Replanning repeated with downscaling of the dwell time until the weight of the needle fell <20% (Needle-Lock plan). The Needle-Lock plans were rescaled to coincide with the high-risk clinical target volumes D90 of clinical plans. D2cc in normal organs and the overdose area >200% of the prescribed dose were evaluated. In 17 of 30 (56.7%) clinical plans, the weight of the needle exceeded 20%. The rectum, bladder and sigmoid colon D2cc significantly increased with the Needle-Lock plan. The overdosage area also increased significantly (P < 0.01). The correlations between the needle number and the increase of D2cc in the rectum and sigmoid colon (P < 0.01) were statistically significant. Limiting needle dwell time weight by 10-20% increased bladder and rectum doses, especially with multiple needles. These findings suggest that needle dwell time weight recommendations could need to be reconsidered based on individual and institutional situation.","PeriodicalId":16922,"journal":{"name":"Journal of Radiation Research","volume":" ","pages":"296-305"},"PeriodicalIF":1.9,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12100482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143997877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Survival outcomes and prognostic factors in bladder cancer treated with radiotherapy. 膀胱癌放射治疗的生存结局和预后因素。

IF 1.9 4区医学

Journal of Radiation Research Pub Date : 2025-05-23 DOI: 10.1093/jrr/rraf018

Koyo Kikuchi, Ibuki Ota, Takafumi Segawa, Yoshiro Ieko, Hirobumi Oikawa, Ryuji Nakamura, Hisanori Ariga

{"title":"Survival outcomes and prognostic factors in bladder cancer treated with radiotherapy.","authors":"Koyo Kikuchi, Ibuki Ota, Takafumi Segawa, Yoshiro Ieko, Hirobumi Oikawa, Ryuji Nakamura, Hisanori Ariga","doi":"10.1093/jrr/rraf018","DOIUrl":"10.1093/jrr/rraf018","url":null,"abstract":"This study evaluated survival outcomes and prognostic factors in patients with bladder cancer treated with radiotherapy. A retrospective analysis was conducted on 488 patients across all cancer stages who received radiotherapy at two institutions between 1 January 2000 and 31 December 2022. Overall survival (OS) was assessed based on treatment intent (radical or palliative) and cancer stage. Among these patients, 304 with Stage II-III disease who underwent radical radiotherapy were further analyzed for OS and prognostic factors using Kaplan-Meier methods and Cox regression analysis. In the radical radiotherapy group, median survival times (MSTs) were 43 months for Stage 0-I, 29 months for Stage II-III, and 17 months for Stage IV (M0). In the palliative radiotherapy group, MSTs were 16 months (95% confidence interval [CI]: 11-25) for M0 and 9 months (95% CI: 7-15) for M1. Among the 304 patients with Stage II-III disease treated with radical radiotherapy, the 3-year OS rate was 43.0%. Hydronephrosis was the only independent prognostic factor significantly associated with worse OS (hazard ratio: 1.915, P < 0.001). Age, sex, stage, treatment era, prophylactic pelvic radiotherapy, chemotherapy and prescribed dose had no significant impact on OS. Radiotherapy remains a viable treatment option for patients at any stage of cancer. Although hydronephrosis negatively affects survival, it should not preclude the use of radiotherapy.","PeriodicalId":16922,"journal":{"name":"Journal of Radiation Research","volume":" ","pages":"272-279"},"PeriodicalIF":1.9,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12100478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0